Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of June 2026
Principal Executive Office: Level 15, 500 Collins Street, Melbourne, Victoria 3000, Australia
Signatory: Julian Babarczy, Chairman (Dated June 15, 2026)
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification regarding unquoted securities rather than a financial results statement.
Material Changes
The filing discloses the submission of Exhibit 99.1, a "Notification regarding unquoted securities - ATH." No other material changes to financial position or operations are detailed in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is incorporated by reference into Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the details of the unquoted securities notification (Exhibit 99.1) referenced in this filing.
- Review the referenced Registration Statements (Form S-8 and Form F-3) for broader context on capital structure.
- Confirm the company's status as a development stage enterprise and its current cash runway, as no financial data is included in this specific 6-K.